SpePharm enters into royalty agreement with Paul Capital
Cancer and critical care company SpePharm Holdings BV has signed a €10mm ($14.75mm) revenue interest acquisition financing with Paul Capital Healthcare to fund SpePharm's recent purchase of European rights to Procter & Gamble's hyperthermia treatment Dantrium. Paul Capital also participated in a simultaneously announced €16mm equity financing for SpePharm, along with other investors.
- Specialty Pharmaceuticals
- Royalty Sale
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com